GlaxoSmithKline plc
GSK
NYSE44.52
GlaxoSmithKline plc
NYSE:GSK
RECENT
PRICE
44.52
P/E
RATIO
17.88
(PEG:-0.74)
P/E RATIO
RELATIVE
TO S&P
0.69
DIV
YLD
3.79%
High:
Low:
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Legends
Stock price
- - Beta (1.0 Market)
0
0
0
0
0
0
0
0
0
% total return 05/22:
Stock
S&P
1y.
0
0
3y.
0
0
5y.
0
0
0
Percent shares traded:
0
0
0
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Fiscal year
8.23
1.91
0.98
0.92
8.23
1.89
1.46
1.01
9.31
1.80
1.96
1.15
11.19
2.18
2.35
1.22
11.16
0.64
2.03
1.26
10.89
2.09
1.96
1.35
10.76
1.86
1.16
1.55
10.97
2.25
2.29
1.52
9.57
1.15
1.42
1.60
9.90
3.49
0.28
1.60
11.48
0.38
1.71
2.00
12.36
0.63
1.93
1.60
12.54
1.47
2.70
1.60
13.65
1.88
2.37
1.60
13.71
2.31
2.49
1.60
13.64
1.75
2.01
1.60
14.56
2.04
2.79
1.60
Revenue per share
Earnings per share
Free Cash Flow per sh
Dividends per share
0.56
3.33
0.78
3.48
0.79
3.03
0.74
3.95
0.64
3.49
0.53
3.19
0.62
2.37
0.70
2.90
0.73
1.77
0.79
2.12
0.97
0.46
0.90
(0.03)
0.73
1.77
0.87
4.61
0.90
5.86
1.17
6.02
1.27
6.19
CAPEX per share
Book Value per share
2,822
2,762
2,616
2,535
2,545
2,514
2,456
2,416
2,404
2,416
2,430
2,443
2,457
2,474
2,488
2,502
2,505
Comm.Shares outs.(m)
28.2
1.6
1.7%
28.3
1.6
1.9%
23.9
1.1
2.7%
16.6
0.2
3.4%
59.3
2.9
3.3%
19.8
1.2
3.3%
24.3
1.6
3.4%
22.1
1.3
3.1%
43.9
2.4
3.2%
12.4
0.6
3.7%
110.1
5.0
4.8%
63.8
2.7
4.0%
26.7
1.1
4.1%
22.1
0.9
3.9%
17.3
0.5
4.0%
22.4
0.7
4.1%
17.9
0.7
3.8%
Avg. annual P/E ratio
P/E relative to S&P500
Avg. annual div. yield
Capital Structure (31/3/22 | Q1)
Total liabilities
$67,057 m.
Total assets
$89,689 m.
Long-term debt
$29,226 m.
Cash and equiv.
$10,967 m.
Goodwill $10,705 m.
Retained earnings $9,637 m.
Common stock 2,510 m. shares
Market Capitalisation
$114,836 m. (as of 21/5/22)
27,387
28.5%
26,431
28.0%
26,505
26.5%
23,006
15.6%
23,923
43.1%
27,889
9.3%
30,186
13.5%
30,821
17.8%
33,754
20.6%
34,099
22.8%
34,114
18.2%
36,476
20.0%
Revenue (m)
Operating margin
1,423
5,261
1,445
4,565
1,414
5,436
1,484
2,756
1,630
8,422
1,774
912
1,922
1,532
1,856
3,623
2,334
4,645
2,351
5,749
2,524
4,385
2,867
5,114
Depreciation (m)
Net profit (m)
29.1%
19.2%
29.1%
17.3%
15.3%
20.5%
4.6%
12.0%
20.5%
35.2%
45.2%
3.3%
38.5%
5.1%
15.7%
11.8%
15.3%
13.8%
8.3%
16.9%
6.4%
12.9%
0.5%
14.1%
Income tax rate
Net profit margin
1,157
12,203
8,032
(123)
14,671
5,810
1,550
15,456
6,997
1,383
15,841
4,263
3,170
15,324
5,114
(2,290)
14,661
1,124
(10,662)
14,264
(68)
(5,564)
20,271
4,360
(4,559)
23,590
11,405
(1,901)
23,425
14,587
(4,996)
20,572
15,055
4,710
29,226
16,181
Working capital (m)
Long-term debt (m)
Equity (m)
23.3%
20.6%
65.5%
19.3%
17.9%
78.6%
22.1%
17.4%
77.7%
12.9%
9.0%
64.6%
24.8%
22.8%
164.7%
3.8%
4.5%
81.1%
8.5%
6.9%
(2,252.9)%
12.0%
8.8%
83.1%
11.3%
8.9%
40.7%
12.7%
9.7%
39.4%
10.5%
7.6%
29.1%
10.8%
7.7%
31.6%
ROIC
Return on capital
Return on equity
Working Capital
2019
2020
2021
Cash assets
4,786
6,171
4,353
Receivables
- -
- -
- -
Inventory
5,947
5,996
5,783
Other
8,758
8,081
8,556
Current assets
19,491
20,247
18,674
Acc. Payable
4,144
4,357
17,554
Debt due
6,918
3,725
3,601
Other
12,988
14,066
2,515
Current liab.
24,050
22,148
23,670
35.3%
108.5%
16.5%
207.7%
32.3%
84.1%
(39.4)%
117.1%
54.0%
583.8%
(431.8)%
116.6%
(155.0)%
83.0%
(8.4)%
58.2%
14.9%
66.6%
30.8%
63.7%
8.8%
79.2%
26.9%
57.1%
Plowback ratio
Div.&Repurch. to FCF
GlaxoSmithKline plc (GB) started trading on September 2, 2001 (cik: 0001131399), operates in the Healthcare sector (Drug Manufacturers—General industry), has 90,096 full-time employees, and is led by Ms. Emma N. Walmsley. GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Annual rates
(avg rate of change)
Past
5 y.
Past
10 y.
Revenues
3.17%
3.17%
Cash flow
3.93%
58.33%
Earnings
41.18%
35.44%
Dividends
0.59%
1.09%
Book value
-1579.77%
-722.43%
Insider trading
Type
Shares
Date
Nothing found
Fiscal Year Ends
Quarterly Revenue (m)
Full fiscal year
I
II
III
IV
2020
9,090
7,624
8,646
8,739
34,099
2021
7,418
8,092
9,077
9,527
34,114
2022
9,780
- -
- -
- -
- -
Fiscal Year Ends
Earnings per share
Full fiscal year
I
II
III
IV
2020
0.63
0.91
0.50
0.27
2.31
2021
0.43
0.56
0.47
0.30
1.75
2022
0.72
- -
- -
- -
- -
Fiscal Year Ends
Quarterly dividends paid
Full fiscal year
I
II
III
IV
2020
0.38
0.46
0.38
0.38
1.60
2021
0.38
0.46
0.38
0.38
1.60
2022
0.38
- -
- -
- -
- -
01/19/2022
Unilever Walks Away From Glaxo Consumer-Healthcare Deal
The Wall Street Journal - Read more...
01/15/2022
Unilever Makes Approach for Glaxo’s Consumer-Healthcare Business
The Wall Street Journal - Read more...
12/07/2021
Tesla, Intel, Bitcoin: What to Watch in the Stock Market Today
The Wall Street Journal - Read more...
12/02/2021
Vir Biotechnology, Digital World Acquisition, Apple: What to Watch in the Stock Market Today
The Wall Street Journal - Read more...
05/17/2021
Sanofi-GSK Covid-19 Vaccine Set for Large-Scale Trials After Positive Results
The Wall Street Journal - Read more...